Fig. 3
From: Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
Cost-effectiveness acceptability curves. TNF tumour necrosis factor, WTP willingness to pay
Fig. 3 | Cost Effectiveness and Resource Allocation